715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study) by Stephane Champiat, Francois-Xavier Danlos, Volker Kunzmann, Martin Wermke, Aude de Gassart, Daniel Olive, Patrick Brune, Emmanuel Valentin, Johann De Bono, Paul Frohna, Marina Iché, Maelle Mairesse, Celine Leparquier, Katrien Lemmens